Schizophrenia: Linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 42, Issue , 2013, Pages 5-19

  Anderson, George ^a   Maes, Michael ^b  

^a CRC   (United Kingdom)

^b Piyavate Hospital   (Thailand)

Author keywords

Cytokines; Neuroprogression; NMDA; Oxidative and nitrosative stress; Schizophrenia; Tryptophan catabolites

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BUNGAROTOXIN RECEPTOR; CLOZAPINE; CYTOKINE; DEXTRO SERINE; KYNURENIC ACID; MELATONIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PREGNENOLONE; QUETIAPINE; RISPERIDONE; TRYPTOPHAN; VITAMIN D; ZINC;

AMINO ACID METABOLISM; ARTICLE; CELL ACTIVATION; CELL INTERACTION; COGNITIVE DEFECT; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; INTERNEURON; INTRAUTERINE INFECTION; MICROGLIA; MYELINATION; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; SCHIZOPHRENIA;

ANIMALS; BRAIN; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; INFECTION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TRYPTOPHAN;

EID: 84873524352     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.014     Document Type: Article

References (229)

1. Adell A., Jiménez-Sánchez L., López-Gil X., Romón T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr Bull 2012, 38(1):9-14.
2. Adib-Conquy M., Cavaillon J.M. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009, 101:36-47.
3. Aguilar-Valles A., Luheshi G.N. Alterations in cognitive function and behavioral response to amphetamine induced by prenatal inflammation are dependent on the stage of pregnancy. Psychoneuroendocrinology 2011, 36:634-648.
4. Aguilar-Valles A., Flores C., Luheshi G.N. Prenatal inflammation-induced hypoferremia alters dopamine function in the adult offspring in rat: relevance for schizophrenia. PLoS One 2010, 5:e10967.
5. Akanji A.O., Ohaeri J.U., Al-Shammri S.N., Fatania H.R. Apolipoprotein E polymorphism and clinical disease phenotypes in Arab patients with schizophrenia. Neuropsychobiology 2009, 60(2):67-72.
6. Alexander K.S., Wu H.Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 2012, 220(3):627-637.
7. Anderson G. Prenatal corticosteroids: pretermer outcomes, stress, schizophrenia, multiple sclerosis and the developmental role of melatonin and Vitamin D3. J Pediatr Adolesc Gynecol 2010, 23(5):317-320.
8. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011, 76:54-60.
9. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012, 27(2):113-119.
10. Anderson G., Ojalla J. Alzheimer's and seizures: interleukin-18, indoleamine 2,3-dioxygenase and quinolinic acid. Int J Trytophan Res 2010, 3:169-173.
11. Anderson G., Rodirguez M. Multiple sclerosis, seizures and anti-epileptics: role of IL-18, IDO and melatonin. Eur J Neurol 2011, 18(5):680-685. [May].
12. Anticevic A, Repovs G, Barch DM. Emotion effects on attention, amygdala activation, and functional connectivity in schizophrenia. Schizophr Bull in press.
13. Appel K., Schwahn C., Mahler B., Mahler J., Schulz A., Spitzer C., et al. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 2011, 36(10):1982-1991.
14. Atkin T.A., Brandon N.J., Kittler J.T. Disrupted in Schizophrenia 1 forms pathological aggresomes that disrupt its function in intracellular transport. Hum Mol Genet 2012, 21(9):2017-2028.
15. Avgustin B., Wraber B., Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 2005, 46(2):268-274.
16. Babulas V., Factor-Litvak P., Goetz R., Schaefer C.A., Brown A.S. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am J Psychiatry 2006, 163:927-929.
17. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006, 163(7):1276-1279.
18. Banerjee J., Alkondon M., Pereira E.F., Albuquerque E.X. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J Pharmacol Exp Ther 2012, 341(2):500-509.
19. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 2012, 62(7):2137-2153.
20. Bencherif M., Stachowiak M.K., Kucinski A.J., Lippiello P.M. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med Hypotheses 2012, 78(5):594-600.
21. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
22. Bernstein H.G., Steiner J., Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009, 9:1059-1071.
23. Bianchi R., Kastrisianaki E., Giambanco I., Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem 2011, 286:7214-7226.
24. Boin F., Zanardini R., Pioli R., Altamura C.A., Maes M. Gennarelli M Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001, 6(1):79-82.
25. Bókkon I., Antal I. Schizophrenia: redox regulation and volume neurotransmission. Curr Neuropharmacol 2011, 9(2):289-300.
26. Boškovic M., Vovk T., Kores Plesnièar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9(2):301-312.
27. Bradshaw N.J., Porteous D.J. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology 2012, 62(3):1230-1241.
28. Bresee C., Rapaport M.H. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 2009, 12:861-865.
29. Brown A.S. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011, 93:23-58.
30. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
31. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011, 37:284-290.
32. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004, 61:774-780.
33. Brown A.S., Hooton J., Schaefer C.A., Zhang H., Petkova E., Babulas V., et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004, 161:889-895.
34. Brown A.S., Vinogradov S., Kremen W.S., Poole J.H., Bao Y., Kern D., et al. Association of maternal genital and reproductive infections with verbal memory and motor deficits in adult schizophrenia. Psychiatry Res 2011, 188(2):179-186.
35. Brune M., Schobel A., Karau R., Benali A., Faustmann P.M., Juckel G., et al. Von Economo neuron density in the anterior cingulate cortex is reduced in early onset schizophrenia. Acta Neuropathol 2010, 119(6):771-778.
36. Brunton P.J., Russell J.A. Attenuated hypothalamo-pituitary-adrenal axis responses to immune challenge during pregnancy: the neurosteroid opioid connection. J Physiol 2008, 586(2):369-375.
37. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Wagner R.L., Yolken R.H. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun 2001, 15:411-420.
38. Byrne M., Agerbo E., Bennedsen B., Eaton W.W., Mortensen P.B. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007, 97(1-3):51-59.
39. Cabungcal J.H., Nicolas D., Kraftsik R., Cuénod M., Do K.Q., Hornung J.P. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 2006, 22:624-637.
40. Carrillo-Vico A., Lardone P.J., Fernandez-Santos J.M., Martin-Lacave I., Calvo J.R., Karasek M., et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metabol 2005, 90(2):992-1000.
41. Chang S.H., Chung Y., Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010, 285(50):38751-38755.
42. Chareyron L.J., Lavenex P.B., Amaral D.G., Lavenex P. Postnatal development of the amygdala: a stereological study in macaque monkeys. J Comp Neurol 2012, 520(9):1965-1984.
43. Charych E.I., Liu F., Moss S.J., Brandon N.J. GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 2009, 57(5-6):481-495.
44. Chen L., Cencioni M.T., Angelini D.F., Borsellino G., Battistini L., Brosnan C.F. Transcriptional profiling of c, d T cells identifies a role for vitamin D in the immunoregulation of the Vg9Vd2 response to phosphonate containing ligands. J Immunol 2005, 174(10):6144-6152.
45. Chen M.L., Tsai T.C., Wang L.K., Lin Y.Y., Tsai Y.M., Lee M.C., et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol 2012, 12(1):197-204.
46. Chen C., Tan B., Zhou Y., Zhou J., He Y., Li S., Ying B., Qin L. IL-28B Genetic Variant Is Associated with the Risk of Schizophrenia in the Chinese Han Population. DNA Cell Bio 2012, 31(6):988-992.
47. Choi Y.B., Lipton S.A. Redox modulation of the NMDA receptor. Cell Mol Life Sci 2000, 57:1535-1541.
48. Clarke M.C., Tanskanen A., Huttunen M., Whittaker J.C., Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry 2009, 166:1025-1030.
49. Coe C.L., Kramer M., Cz,h B., Gould E., Reeves A.J., Kirschbaum C., et al. Prenatal stress diminishes neurogenesis in the dentate gyrus of juvenile rhesus monkeys. Biol Psychiatry 2003, 54(10):1025-1034.
50. Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011, 14:756-767.
51. Copeland CS, Neale SA, Salt TE. Actions of Xanthurenic Acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. Neuropharmacology in press.
52. Coyle P., Tran N., Fung J.N., Summers B.L., Rofe A.M. Maternal dietary zinc supplementation prevents aberrant behavior in an object recognition task in mice offspring exposed to LPS in early pregnancy. Behav Brain Res 2009, 197:210-218.
53. Cui H., Nishiguchi N., Yanagi M., Fukutake M., Mouri K., Kitamura N., et al. A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr Res 2010, 121:172-178.
54. Davidson M.E., Kerepesi L.A., Soto A., Chan V.T. d-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats. Arch Toxicol 2009, 83(8):747-762.
55. de la Fuente-Sandoval C., Lecn-Ortiz P., Favila R., Stephano S., Mamo D., Ramirez-Bermudez J., et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
56. Dean B., Digney A., Sundram S., Thomas E., Scarr E. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res 2008, 158(1):75-78.
57. Deng W. Neurobiology of injury to the developing brain. Nat Rev Neurol 2010, 6:328-336.
58. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
59. Di Serio C., Cozzi A., Angeli I., Doria L., Micucci I., Pellerito S., et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol 2005, 25(6):981-993.
60. Dietschy J.M., Turley S.D. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004, 45(8):1375-1397.
61. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
62. Doherty G.H. Developmental switch in the effects of TNFalpha on ventral midbrain dopaminergic neurons. Neurosci Res 2007, 57:296-305.
63. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 2011, 24:1-10.
64. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
65. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23(2):91-101.
66. Esposito P., Chandler N., Kandere K., Basu S., Jacobson S., Connolly R., et al. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303:1061-1066.
67. Fatemi S.H., Araghi-Niknam M., Laurence J.A., Stary J.M., Sidwell R.W., Lee S. Glial fibrillary acidic protein and glutamic acid decarboxylase 65 and 67kDa proteins are increased in brains of neonatal BALB/c mice following viral infection in utero. Schizophr Res 2004, 69:121-123.
68. Feng C.-Y., Wiggins L.M., von Bartheld C.S. The locus coeruleus responds to signaling molecules obtained from the CSF by transfer through tanycytes. J Neurosci 2011, 31(25):9147-9158.
69. Fiore M., Di Fausto V., Iannitelli A., Aloe L. Clozapine or Haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations. Ann Ist Super Sanita 2008, 44(2):167-177.
70. Fleck D., Garratt A.N., Haass C., Willem M. BACE1 Dependent neuregulin proteolysis. Curr Alzheimers Res 2012, 9(2):178-183.
71. Frommberger U.H., Bauer J., Haselbauer P., Frulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247:228-233.
72. Gal E., Sherman A.D. L-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980, 5:223-239.
73. Gandhi R., Hayley S., Gibb J., Merali Z., Anisman H. Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain Behav Immun 2007, 21(4):477-489.
74. Ganz T., Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009, 46:387-393.
75. Garcia-Bueno B., Caso J.R., Leza J.C. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci Biobehav Rev 2008, 32:1136-1151.
76. Garcia-Mauriño S., Gonzalez-Haba M.G., Calvo J.R., Rafii-el-Idrissi M., Sanchez-Margalet V., Goberna R., et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997, 159:574-581.
77. Garver D.L., Holcomb J.A., Christensen J.D. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008, 11(1):49-61.
78. Gee D.G., Karlsgodt K.H., van Erp T.G., Bearden C.E., Lieberman M.D., Belger A., et al. Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study. Schizophr Res 2012, 134(1):1-9.
79. Gegg M.E., Beltran B., Salas-Pino S., Bolanos J.P., Clark J.B., Moncada S., et al. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?. J Neurochem 2003, 86(1):228-237.
80. Girard S., Tremblay L., Lepage M., Sébire G. IL-1 receptor antagonist protects against placental and neurodevelopmental defects induced by maternal inflammation. J Immunol 2010, 184:3997-4005.
81. Goritz C., Mauch D.H., Nagler K., Pfrieger F.W. Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. J Physiol Paris 2002, 96(3-4):257-263.
82. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007, 104:16621-16626.
83. Harvey L., Boksa P. A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology 2012, 62(4):1767-1776.
84. Hashimoto M., Sagara Y., Langford D., Everall I.P., Mallory M., Everson A., et al. Fibrobals growth factor 1 regulates signalling via glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 2002, 277(36):32985-32991.
85. Hertz L. Isotope-based quantitation of uptake, release, and metabolism of glutamate and glucose in cultured astrocytes. Methods Mol Biol 2012, 814:305-323.
86. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metabol Clin North Am 2010, 39(2):365-379.
87. Hsiao E.Y., Patterson P.H. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun 2011, 25(4):604-615.
88. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008, 34:354-366.
89. Ibi D., Nagai T., Nabeshima T., Yamada K. PolyI:C-induced neurodevelopmental animal model for schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi 2011, 31(5-6):201-207. [Nov].
90. Igue R., Potvin S., Bah R., Stip E., Bouchard R.H., Lipp O., et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(7):1695-1698.
91. Jarskog L.F., Xiao H., Wilkie M.B., Lauder J.M., Gilmore J.H. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 1997, 15:711-776.
92. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
93. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009, 183(9):5458-5467.
94. Jessen F, Fingerhut N, Sprinkart AM, Kühn KU, Petrovsky N, Maier W, Schild HH, Block W, Wagner M, Träber F. N-Acetylaspartylglutamate (NAAG) and N-Acetylaspartate (NAA) in patients with schizophrenia. Schizophr Bull in press.
95. Jin C.Y., Lee J.D., Park C., Choi Y.H., Kim G.Y. Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin 2007, 28(10):1645-1651.
96. Juckel G., Manitz M.P., Brcne M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia: a pilot study. Schizophr Res 2011, 131:96-100.
97. Jungerius B.J., Hoogendoorn M.L., Bakker S.C., Van't Slot R., Bardoel A.F., Ophoff R.A., et al. An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatry 2008, 13(11):1060-1068.
98. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem 2008, 106:815-825.
99. Kato T.A., Monji A., Mizoguchi Y., Hashioka S., Horikawa H., Seki Y., Kasai M., Utsumi H., Kanba S. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?. Mini Rev Med Chem 2011, 11(7):565-574.
100. Kim J., Kornhuber H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20:379-382.
101. Kinukawa H., Jikou T., Nitta A., Furukawa Y., Hashimoto M., Fukumitsu H., et al. Cyclic AMP/protein kinase a signal attenuates Ca(2+)-induced fibroblast growth factor-1 synthesis in rat cortical neurons. J Neurosci Res 2004, 77(4):487-497.
102. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C et al. Systemic immune challenge trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation in press.
103. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003, 169(3-4):215-233.
104. Kucinski A., Syposs C., Wersinger S., Bencherif M., Stachowiak M.K., Stachowiak E.K. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophr Res 2012, 136(1-3):82-87.
105. Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull in press.
106. Lai I.C., Chen M.L., Wang Y.C., Chen J.Y., Liao D.L., Bai Y.M., et al. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. World J Biol Psychiatry 2011, 12(2):143-148.
107. Lalor S.J., Dungan L.S., Sutton C.E., Basdeo S.A., Fletcher J.M., Mills K.H. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 2011, 186(10):5738-5748.
108. Lanté F., Meunier J., Guiramand J., De Jesus Ferreira M.C., Cambonie G., Aimar R., et al. Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation. Hippocampus 2008, 18:602-609.
109. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210(1):84-91.
110. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: Focus on individual differences. Pharmacol Biochem Behav 2011, 98:161-168.
111. Lavoie S., Allaman I., Petit J.M., Do K.Q., Magistretti P.J. Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia. PLoS One 2011, 6(7):e22875.
112. Le Hellard S., Muhleisen T.W., Djurovic S., Ferno J., Ouriaghi Z., Mattheisen M., et al. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcriptions factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry 2010, 15(5):463-472.
113. Leask S.J., Done D.J., Crow T.J. Adult psychosis, common childhood infections and neurological soft signs in a national birth cohort. Br J Psychiatry 2002, 181:387-392.
114. Lee M., Kang Y., Suk K., Schwab C., Yu S., McGeer P.L. Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J Biol Chem 2011, 286(48):41230-41245.
115. Lee M., Jayathilake K., Dai J., Meltzer H.Y. Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Res 2011, 185(3):328-333.
116. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
117. LeWinn K.Z., Stroud L.R., Molnar B.E., Ware J.H., Koenen K.C., Buka S.L. Elevated maternal cortisol levels during pregnancy are associated with reduced childhood IQ. Int J Epidemiol 2009, 38(6):1700-1710.
118. Li W., Yamamoto H., Kubo S., Okamura H. Modulation of innate immunity by IL-18. J Reprod Immunol 2009, 83(1-2):101-105.
119. Lissoni P., Rovelli F., Giani L., Fumagalli L., Mandal M. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. Nat Immun 1998, 16(5-6):178-184.
120. Liu J., Liu J., Zhou Y., Li S., Li Y., Song X., et al. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol 2011, 30(11):913-917.
121. Liu N.Q., Kaplan A.T., Lagishetty V., Ouyang Y.B., Ouyang Y., Simmons C.F., et al. Vitamin D and the regulation of placental inflammation. J Immunol 2011, 186(10):5968-5974.
122. Lü L.X., Guo S.Q., Chen W., Li Q., Cheng J., Guo J.H. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao 2004, 24(11):1251-1254.
123. Luchowska E., Kloc R., Olajossy B., Wnuk S., Wielosz M., Owe-Larsson B., et al. Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):519-529.
124. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994, 89:346-351.
125. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995, 244(6):325-329.
126. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996, 21(1):39-50.
127. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997, 26(2-3):221-225.
128. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000, 10(2):119-124.
129. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):659-663.
130. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new 5-HT hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):702-721.
131. Maldonado M.D., Perez-San-Gregorio M.A., Reiter R.J. The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discov 2009, 4(1):61-69.
132. Mandal M., Marzouk A.C., Donnelly R., Ponzio N.M. Preferential development of Th17 cells in offspring of immunostimulated pregnant mice. J Reprod Immunol 2010, 87(1-2):97-100.
133. Marx C.E., Bradford D.W., Hamer R.M., Naylor J.C., Allen T.B., Lieberman J.A., et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011, 191:78-90.
134. Matilainen J.M., R,s,nen A., Gynther P., V,is,nen S. The genes encoding cytokines IL-2, IL-10 and IL-12B are primary 1alpha,25(OH)2D3 target genes. J Steroid Biochem Mol Biol 2010, 121(1-2):142-145.
135. Matrisciano F, Tueting P, Dalal I, Kadriu B, Grayson DR, Davis JM, Nicoletti F, Guidotti A. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology in press.
136. Menon R.R., Barta P.E., Aylward E.H., Richards S.S., Vaughn D.D., Tien A.Y., et al. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr Res 1995, 16(2):127-135.
137. Meyer U. Developmental neuroinflammation and schizophrenia. Progress in Neuropsychopharmacol Biol Psychiatry 2013, 42:20-34. (this issue).
138. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010, 90:285-326.
139. Meyer U., Murray P.J., Urwyler A., Yee B.K., Schedlowski M., Feldon J. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 2008, 13:208-221.
140. Meyer U., Engler A., Weber L., Schedlowski M., Feldon J. Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 2008, 154:701-709.
141. Meyer U., Nyffeler M., Schwendener S., Knuesel I., Yee B.K., Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008, 33:441-456.
142. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
143. Miller B.H., Zeier Z., Xi L., Lanz T.A., Deng S., Strathmann J., et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012, 109(8):3125-3130. [Feb 21].
144. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003, 40:881-884.
145. Moghaddam B., Javitt D. From Revolution to Evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacol Rev 2012, 37:4-15.
146. Moller M., Du Preez J.L., Emsley R., Harvey B.H. Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Neuropharmacology 2012, 62(8):2499-2506.
147. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: micro-glia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
148. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-121. (this issue).
149. Muller N., Schlesinger B.C., Hadjamu M., Riedel M., Schwarz M., Ackenheil M., et al. The increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ γδ+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain-barrier and HLA-DPA*02011. Schizophr Res 1998, 32:69-71.
150. Muller N., Myint A.M., Schwarz M.J. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011, 17:130-136.
151. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 2011, 25(8):1576-1581.
152. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
153. Nikopoulos G.N., Duarte M., Kubu C.J., Bellum S., Friesel R., Maciag T., et al. Soluble Jagged1 attenuates lateral inhibition, allowing for the clonal expansion of neural crest stem cells. Stem Cells 2007, 25(12):3133-3142.
154. Ojala J.O., Sutinen E.M., Salminen A., Pirttilä T. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol 2008, 205(1-2):86-93.
155. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008, 63(1):86-91.
156. Osaki R., Nishimura T., Shioya M., Takeuchi T., Okumura Y., Nakahara T., et al. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection. Mol Med Rep 2012, 5(2):525-528.
157. Pacheco-Lopez G, Giovanoli S, Langhans W, Meyer U. Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr Bull in press.
158. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 2006, 6:666-671.
159. Pankhurst M.W., Bennett W., Kirkcaldie M.T., West A.K., Chung R.S. Increased circulating leukocyte numbers and altered macrophage phenotype correlate with the altered immune response to brain injury in metallothionein (MT)-I/II null mutant mice. J Neuroinflammation 2011, 8:172.
160. Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011, 45(2):304-308.
161. Patil S., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13(9):1102-1107.
162. Petitto J.M., Huang Z., Meola D., Ha G.K., Dauer D. Interleukin-2 and the septohippocampal system: intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders. Methods Mol Biol 2012, 829:433-443.
163. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006, 40:725-741.
164. Pierri J.N., Chaudry A.S., Woo T.U., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999, 156(11):1709-1719.
165. Pioli C., Caroleo M.C., Nistico G., Doria G. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993, 15:463-468.
166. Pocivavsek A., Wu H.Q., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 2012, 35(10):1605-1612.
167. Pollard M., Varin C., Hrupka B., Pemberton D.J., Steckler T., Shaban H. Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia. Behav Brain Res 2012, 227(1):184-193.
168. Pontes G.N., Cardoso E.C., Carneiro-Sampaio M.M., Markus R.P. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 2007, 43:365-371.
169. Potter E.D., Ling Z.D., Carvey P.M. Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res 1999, 296:235-246.
170. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
171. Prasad A.S. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care 2009, 12:646-652.
172. Procyshyn R.M., Wasan K.M., Thornton A.E., Barr A.M., Chen E.Y., Pomarol-Clotet E., et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007, 32(5):331-338.
173. Rahman M.A., Azuma Y., Fukunaga H., Murakami T., Sugi K., Fukushi H., et al. Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia. J Antimicrob Chemother 2005, 56(5):861-868.
174. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
175. Raskind M.A., Burke B.L., Crites N.J., Tapp A.M., Rasmussen D.D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007, 32:284-288.
176. Read J., Perry B.D., Moskowitz A., Connolly J. The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. Psychiatry 2001, 64:319-345.
177. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011, 12:13.
178. Reif A., Herterich S., Strobel A., Ehlis A.C., Saur D., Jacob C.P., et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 2006, 11:286-300.
179. Reif A., Schecklmann M., Eirich E., Jacob C.P., Jarczok T.A., Kittel-Schneider S., et al. A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia. Int J Neuropsychopharmacol 2011, 14:887-897.
180. Romero E., Guaza C., Castellano B., Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry 2010, 15:372-383.
181. Saadani-Makki F., Kannan S., Lu X., Janisse J., Dawe E., Edwin S., et al. Intrauterine administration of endotoxin leads to motor deficits in a rabbit model: a link between prenatal infection and cerebral palsy. Am J Obstet Gynecol 2008, 199(651):e1-e7.
182. Samuelsson A.M., Jennische E., Hansson H.A., Holm,ng A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1345-R1356.
183. Sathyasaikumar K.V., Stachowski E.K., Wonodi I., Roberts R.C., Rassoulpour A., McMahon R.P., et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011, 37(6):1147-1156.
184. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 2008, 105(14):5585-5590.
185. Scheel M, Prokscha T, Bayerl M, Gallinat J, Montag C. Myelination deficits in schizophrenia: evidence from diffusion tensor imaging. Brain Struct Funct in press.
186. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56:483-486.
187. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001, 58(11):1049-1052.
188. Shibata K. Close link between development and function of γ-δ T cells. Microbiol Immunol 2012, 56(4):217-227.
189. Shibata K., Yamada H., Sato T., Dejima T., Nakamura M., Ikawa T., et al. Notch-Hes1 pathway is required for the development of IL-17-producing T cells. Blood 2011, 118(3):586-593.
190. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45:135-141.
191. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
192. Smith M.J., Horan W.P., Karpouzian T.M., Abram S.V., Robia D.J., Csernansky J.G. Self-reported empathy deficits are uniquely associated with poor functioning in schizophrenia. Schizophr Res 2012, 137(1-3):196-202.
193. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009, 65:481-488.
194. Soumiya H., Fukumitsu H., Furukawa S. Prenatal immune challenge compromises development of upper-layer but not deeper-layer neurons of the mouse cerebral cortex. J Neurosci Res 2011, 89:1342-1350.
195. Soumiya H., Fukumitsu H., Furukawa S. Prenatal immune challenge compromises the normal course of neurogenesis during development of the mouse cerebral cortex. J Neurosci Res 2011, 89:1575-1585.
196. Srinivasan V., Spence D.W., Trakht I., Pandi-Perumal S.R., Cardinali D.P., Maestroni G.J. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008, 15:93-101.
197. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42(2):151-157.
198. Steullet P., Neijt H.C., Cuenod M., Do K.Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006, 137:807-819.
199. Svedin P., Kjellmer I., Welin A.K., Blad S., Mallard C. Maturational effects of lipopolysaccharide on white-matter injury in fetal sheep. J Child Neurol 2005, 20:960-964.
200. Takano A., Arakawa R., Ito H., Tatcno A., Takahashi H., Matsumoto R., et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C950. J Neuropsychopharmacol 2010, 13(1):943-950.
201. Takatsu Y., Fujita Y., Tsukamoto T., Slusher B.S., Hashimoto K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Res 2011, 1371:82-86.
202. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., Okada M. Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012, 165(5):1543-1555.
203. Taneli F., Pirildar S., Akdeniz F., Uyanik B.S., Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004, 35(5):401-405.
204. Tohmi M., Tsuda N., Zheng Y., Mizuno M., Sotoyama H., Shibuya M., et al. The cellular and behavioral consequences of interleukin-1 alpha penetration through the blood-brain barrier of neonatal rats: a critical period for efficacy. Neuroscience 2007, 150(1):234-250.
205. Traynor T.R., Majde J.A., Bohnet S.G., Krueger J.M. Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. Life Sci 2004, 74:2563-2576.
206. Trecartin K.V., Bucci D.J. Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr Res 2011, 133(1-3):156-158.
207. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11 C] PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822.
208. van Buuren M., Vink M., Rapcencu A.E., Kahn R.S. Exaggerated brain activation during emotion processing in unaffected siblings of patients with schizophrenia. Biol Psychiatry 2011, 70(1):81-87.
209. van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A.B. Inflammasome activation and IL-1b and IL-18 processing during infection. Trends Immunol 2011, 32(3):110-116.
210. van Oel C.J., Sitskoorn M.M., Cremer M.P., Kahn R.S. School performance as a premorbid marker for schizophrenia: a twin study. Schizophr Bull 2002, 28(3):401-414.
211. Vik-Mo A.O., Fern> J., Skrede S., Steen V.M. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009, 9:10.
212. Vogel M., Meier J., Gr"nke S., Waage M., Schneider W., Freyberger H.J., et al. Differential effects of childhood abuse and neglect: mediation by posttraumatic distress in neurotic disorder and negative symptoms in schizophrenia. Psychiatry Res 2011, 189(1):121-127.
213. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
214. Winter C., Reutiman T.J., Folsom T.D., Sohr R., Wolf R.J., Juckel G., et al. Dopamine and serotonin levels following prenatal viral infection in mouse: implications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol 2008, 18:712-716.
215. Winter C., Djodari-Irani A., Sohr R., Morgenstern R., Feldon J., Juckel G., et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009, 12:513-524.
216. Wolf D.H., Satterthwaite T.D., Loughead J., Pinkham A., Overton E., Elliott M.A., et al. Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge. Psychopharmacology (Berl) 2011, 218(3):503-512.
217. Wolff A.R., Cheyne K.R., Bilkey D.K. Behavioural deficits associated with maternal immune activation in the rat model of schizophrenia. Behav Brain Res 2011, 225:382-387.
218. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 2010, 36:211-218.
219. Wonodi I., Stine O.C., Sathyasaikumar K.V., Roberts R.C., Mitchell B.D., Hong L.E., et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011, 68(7):665-674.
220. Wood S.J., Pantelis C., Velakoulis D., Yccel M., Fornito A., McGorry P.D. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr Bull 2008, 34:322-329.
221. Wyatt R.J. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 1991, 5:201-202.
222. Xu M.Q., St Clair D., He L. Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. Schizophr Res 2006, 84(2-3):228-235.
223. Yang Y., Hahm E., Kim Y., Kang J., Lee W., Han I., et al. Regulation of IL-18 expression by CRH in mouse microglial cells. Immunol Lett 2005, 98(2):291-296.
224. Yao J.K., Leonard S., Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30(4):923-934.
225. Yokley J.L., Prasad K.M., Thowdari K.V., Talkowski M.E., Wood J., Gur R.E., et al. Genetic associations between neuregulin-1 SNPs and neurocognitive function in multigenerational, multiplex schizophrenia families. Psychiatr Genet 2012, 22(2):70-81.
226. You Z., Luo C., Zhang W., Chen Y., He J., Zhao Q., et al. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res 2011, 225(1):135-141.
227. Zaharieva I., Georgieva L., Nikolov I., Kirov G., Owen M.J., O'Donovan M.C., et al. Association study in the 5q31-32 linkage region for schizophrenia using pooled DNA genotyping. BMC Psychiatry 2008, 8:11.
228. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004, 65(7):940-947.
229. Zhang J., Chen J., Xu Q., Shen Y. Does the presenilin 2 gene predispose to schizophrenia?. Schizophr Res 2009, 109(1-3):121-129.